Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients

Neurosci Lett. 2003 Mar 20;339(2):99-102. doi: 10.1016/s0304-3940(02)01483-0.

Abstract

Biomarkers to monitor the degenerative process in Alzheimer's disease would be of great value. We examined the relation between cerebrospinal fluid (CSF) total tau (T-tau), phospho-tau (P-tau) and Abeta42 and magnetic resonance imaging (MRI) measures of brain atrophy. CSF was taken at baseline and MRI at baseline and at 16 months follow-up. At baseline, statistically significantly lower Abeta42 were found with lower brain volume (r=0.55; P<0.0001) and larger ventricular volume (r=-0.53; P<0.001). In contrast, statistically significantly higher T-tau (r=0.47; P<0.001) and P-tau (r=0.41; P=0.005) were found with more marked ventricular widening during the follow-up period. These results suggest that Abeta42 in CSF reflects the stage of the disease, with lower CSF levels as the disease progresses, while T-tau and P-tau reflect the intensity of the disease process, with higher CSF-levels with a more rapid progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / complications
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Atrophy
  • Biomarkers / cerebrospinal fluid
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / etiology
  • Cognition Disorders / pathology
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Peptide Fragments / cerebrospinal fluid*
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins